Zymeworks (ZYME) Competitors $14.30 +0.36 (+2.58%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$14.30 +0.00 (+0.03%) As of 08/14/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. MENS, MLTX, MTSR, PTGX, APLS, SRRK, MIRM, MOR, NAMS, and AMRXShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Jyong Biotech (MENS), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), and AMNEAL PHARMACEUTICALS (AMRX). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors Jyong Biotech MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Apellis Pharmaceuticals Scholar Rock Mirum Pharmaceuticals MorphoSys NewAmsterdam Pharma AMNEAL PHARMACEUTICALS Jyong Biotech (NASDAQ:MENS) and Zymeworks (NYSE:ZYME) are both pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability. Do insiders & institutionals have more ownership in MENS or ZYME? 92.9% of Zymeworks shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend MENS or ZYME? Zymeworks has a consensus target price of $21.43, indicating a potential upside of 49.85%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Is MENS or ZYME more profitable? Jyong Biotech has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Jyong Biotech's return on equity of 0.00% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Zymeworks -182.75%-23.00%-18.04% Does the media favor MENS or ZYME? In the previous week, Zymeworks had 10 more articles in the media than Jyong Biotech. MarketBeat recorded 19 mentions for Zymeworks and 9 mentions for Jyong Biotech. Zymeworks' average media sentiment score of 0.48 beat Jyong Biotech's score of 0.34 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has better earnings & valuation, MENS or ZYME? Jyong Biotech has higher earnings, but lower revenue than Zymeworks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AZymeworks$122.87M8.75-$118.67M-$0.97-14.74 SummaryZymeworks beats Jyong Biotech on 9 of the 12 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.07B$791.77M$5.61B$21.04BDividend YieldN/A4.84%4.61%3.56%P/E Ratio-9.531.1830.2928.01Price / Sales8.7526.06463.4157.05Price / CashN/A19.5638.2123.95Price / Book2.166.588.825.26Net Income-$118.67M-$4.98M$3.25B$994.11M7 Day Performance18.97%1.86%3.70%2.09%1 Month Performance11.02%0.45%5.84%2.35%1 Year Performance36.19%16.14%29.92%13.36% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks3.2497 of 5 stars$14.30+2.6%$21.43+49.9%+41.0%$1.07B$122.87M-9.53460MENSJyong BiotechN/A$49.56+9.3%N/AN/A$3.45BN/A0.0031News CoverageGap DownHigh Trading VolumeMLTXMoonLake Immunotherapeutics2.554 of 5 stars$53.38+1.9%$74.43+39.4%+16.8%$3.35BN/A-19.202Analyst RevisionMTSRMetseraN/A$30.14-0.9%$55.00+82.5%N/A$3.19BN/A0.0081PTGXProtagonist Therapeutics2.036 of 5 stars$53.75+5.2%$67.20+25.0%+36.7%$3.18B$434.43M76.79120Positive NewsAPLSApellis Pharmaceuticals4.0083 of 5 stars$23.85-2.1%$34.12+43.1%-23.3%$3.08B$781.37M-13.10770Short Interest ↑SRRKScholar Rock4.481 of 5 stars$31.46-1.5%$45.14+43.5%+250.6%$3.07B$33.19M-10.81140Positive NewsAnalyst RevisionMIRMMirum Pharmaceuticals3.9935 of 5 stars$65.87+9.8%$74.13+12.5%+56.3%$3.01B$336.89M-54.44140Insider TradeHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730NAMSNewAmsterdam Pharma3.5361 of 5 stars$24.37-3.7%$41.20+69.1%+48.1%$2.84B$45.56M-15.044AMRXAMNEAL PHARMACEUTICALS3.0677 of 5 stars$8.84+3.5%$11.60+31.2%+20.2%$2.68B$2.79B884.888,100News CoverageInsider Trade Related Companies and Tools Related Companies MENS Alternatives MLTX Alternatives MTSR Alternatives PTGX Alternatives APLS Alternatives SRRK Alternatives MIRM Alternatives MOR Alternatives NAMS Alternatives AMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access